Empegfilgrastim

DB16155Investigational

Empegfilgrastim is under investigation in clinical trial NCT01569087 (Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer).

Mechanism: Pharmacologically active on Granulocyte colony-stimulating factor receptor
Curator reviewed
Also known as: Colony-stimulating factor, granulocyte (synthetic human), 30-kilodalton pegylated

Resolves to

Compound

UNIIF0B69ZZ07ACAS1192706-53-8

Clinical / RWD

ATCL03AA16

Targets

Q99062CSF3R

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 3 drug categories

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Empegfilgrastim, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account